Bambusa Therapeutics

Bambusa develops bispecific antibodies for I&I disorders. Its lead product targets IL-4Ra and IL-31 for atopic dermatitis and pruritus.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2025
Bambusa Portco Hover Image